Despite declining transaction volume in 2024, life sciences companies are pursuing bigger acquisitions to secure drug portfolios, integrate AI capabilities, and navigate the looming patent cliff.
Learn how a RMIS can strengthen cross-functional alignment across risk, safety, finance, operations, and IT; reduce reliance on manual processes; and support more confident, informed leadership discussions.
Delaying adoption creates real competitive risk, widening gaps in severity management, settlement outcomes, expense control, workforce productivity, and market credibility. AI maturity is increasingly separating leaders from followers.
Executives are navigating intense day-to-day operational pressures that are crowding out a focus on high-impact risks like litigation, even as they recognize those risks could threaten their company’s survival.
As AI reshapes the claims landscape, one executive explains how data-driven tools are enhancing — not replacing — the judgment and empathy that define exceptional claims handling.
AI in claims is no longer about insight alone — it’s about embedding intelligence into everyday workflows to drive faster decisions, stronger outcomes, and more human-centered care.